Earnings Releases·Nov 12, 2026, 8:25 AM ET

SpyGlass Pharma — Third Quarter 2026 Earnings Summary

Cash, cash equivalents, and short-term investments increased to $215.8 million as of September 30, 2026, from $107.4 million at year-end 2025, while stockholders' equity turned positive to $210.4 million compared to a $98.8 million deficit previously.
Net loss for the quarter widened to $24.3 million ($0.73 per share) from $9.8 million ($4.53 per share) in the prior year period, driven by a 46% increase in total operating expenses to $26.2 million.
The company acquired Advanced Vision Science, Inc. for approximately $13 million in October to secure scalable IOL manufacturing capacity and supply for Phase 3 trials.
Cash reserves are projected to fund operations through 2028, with Phase 3 trial completion expected in 2027 and preliminary BIM-DRS safety data anticipated the same year.
Strategic progress includes four-year BIM-IOL FIH data showing a 37% IOP reduction and 86% of patients drop-free, alongside completed first implantations of the BIM-DRS system.